Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants

NCT00896740 | Terminated DMC

• 3 other identifiers: IRB00000713OHSU-HEM-01079-LCDR0000445212
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

RATIONALE: Studying samples of bone marrow from patients with Fanconi anemia and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to Fanconi anemia. PURPOSE: This laboratory study is evaluating gene function in bone marrow cells from patients with Fanconi anemia and from healthy participants.

Conditions

Fanconi Anemia

Keywords

Fanconi anemia

Outcome Measures

Primary Outcomes (3)

• Comparison of Fanconi anemia (FA) hematopoietic cells vs normal hematopoietic cells

• Comparison of FA hematopoietic cells from children with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) vs children (siblings) with FA but without MDS/AML

• Comparison of FA cells from different complementation groups

Interventions

microarray analysis GENETIC

biopsy PROCEDURE

Eligibility Criteria

• Age: 1 Year - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

FA Patients are recruited from OHSU Clinics. Healthy Normal donors are recruited with an IRB approved advertisement which runs in the Outlook and is posted on bulletin boards around campus

DISEASE CHARACTERISTICS: * Meets 1 of the following criteria: * Diagnosis of Fanconi anemia * Requires bone marrow aspiration or biopsy for clinical purposes * Healthy volunteer * Over 18 years of age * No known blood abnormality PATIENT CHARACTERISTICS: * Platelet count \> 150,000/mm\^3 * White Blood Cell(WBC) \> 4,000/mm\^3 * Hemoglobin \> 13 g/dL * No clinical signs or symptoms of acute or subacute infection (e.g., viral, bacterial, or fungal) * No allergies to lidocaine or xylocaine PRIOR CONCURRENT THERAPY: * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• OHSU Knight Cancer Institute: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Knight Cancer Institute at Oregon Health and Science University

Portland, Oregon, 97239-3098, United States

Location

MeSH Terms

Conditions

Fanconi Anemia

Interventions

Microarray Analysis; Biopsy

Condition Hierarchy (Ancestors)

Anemia, Hypoplastic, Congenital; Anemia, Aplastic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Congenital Bone Marrow Failure Syndromes; Bone Marrow Failure Disorders; Bone Marrow Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; DNA Repair-Deficiency Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Microchip Analytical Procedures; Investigative Techniques; Cytodiagnosis; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Specimen Handling; Diagnostic Techniques, Surgical; Surgical Procedures, Operative

Study Officials

• Grover C. Bagby, MD

  OHSU Knight Cancer Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor Emeritus

Study Record Dates

• First Submitted: May 9, 2009
• First Posted: May 12, 2009
• Study Start: March 1, 2002
• Primary Completion: September 1, 2007
• Study Completion: September 1, 2007
• Last Updated: December 4, 2017

Record last verified: 2017-11

Locations

US (1)